Skip to main content
OpenTrials

Clinical trial condition

Diffuse Large B-cell Lymphoma

Explore clinical trials studying Diffuse Large B-cell Lymphoma. Study availability and eligibility vary by location and protocol.

213 public trials 54 recruiting studies
Refine in advanced search Browse all conditions

Diffuse Large B-cell Lymphoma trial results

Completed

Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma

NCT00556127

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • Az. Ospedaliera SS. Antonio e Biagio e Cesare Arrigo Alessandria, Italy
  • Ospedale Regionale, Divisione di Oncologia, Aosta, Italy
  • Azienda Ospedaliera Ospedale Policlinico Consorziale Bari, Italy
  • Osp. degli Infermi Biella, Italy
View all 14 locations
View Trial Details
Active, Not Recruiting

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

NCT03984448

Conditions
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Diffuse Large B-cell Lymphoma, Double-Expressor Lymphoma, +16 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
View all 635 locations
View Trial Details
Active, Not Recruiting

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

NCT04404283

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Central Alabama Research Birmingham, Alabama, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • University of California Davis Medical Center Sacramento, California, United States
  • Florida Cancer Specialists Bonita Springs, Florida, United States
View all 143 locations
View Trial Details
Active, Not Recruiting

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT04408638

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Community Cancer Institute (CCI) Fresno, California, United States
  • Baptist - MD Anderson Cancer Center Jacksonville, Florida, United States
  • University of Maryland Medical Center Baltimore, Maryland, United States
View all 63 locations
View Trial Details
Active, Not Recruiting

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

NCT04663347

Conditions
Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Hemic and Lymphatic Diseases, +11 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Cedars-Sinai Medical Center Los Angeles, California, United States
  • David Geffen School of Medicine at UCLA Los Angeles, California, United States
  • University of California San Francisco San Francisco, California, United States
View all 57 locations
View Trial Details
Active, Not Recruiting

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02227251

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • UACC Arizona Tucson, Arizona, United States
  • University of California San Francisco San Francisco, California, United States
  • University of California Los Angeles (UCLA) Santa Monica, California, United States
  • Boca Raton Cancer Research Medical Center Plantation, Florida, United States
View all 175 locations
View Trial Details
Active, Not Recruiting

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

NCT04529772

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Research Site Tucson, Arizona, United States
  • Research Site Little Rock, Arkansas, United States
  • Research Site Irvine, California, United States
  • Research Site Aurora, Colorado, United States
View all 243 locations
View Trial Details
Active, Not Recruiting

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

NCT01787409

Conditions
Aggressive Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, +40 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Emory University/Winship Cancer Institute Atlanta, Georgia, United States
  • University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa, United States
  • Mayo Clinic Rochester, Minnesota, United States
View Trial Details

Related conditions